E7386 enhances lenvatinib’s antitumor activity in preclinical models and human hepatocellular carcinoma.
RNA-seq (gene expression) · mouse · 44 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Topic
- Hepatocellular carcinomaThis series is part of our curated briefing on it.
- Samples
- 44 samples: 12 conditions, mostly with about 4 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular CarcinomaClinical cancer research : an official journal of the American Association for Cancer Research · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE299215_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1273097 and SRA study SRP590410. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 43 samples.
How we read this: 12 replicated groups read from 44 sample titles; they account for 43 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9035232 Huh7, DMSO-treated, 1 Huh7, DMSO-treated,
- GSM9035233 Huh7, DMSO-treated, 2 Huh7, DMSO-treated,
- GSM9035234 Huh7, DMSO-treated, 3 Huh7, DMSO-treated,
- GSM9035235 Huh7, DMSO-treated, 4 Huh7, DMSO-treated,
- GSM9035236 Huh7, E7386-treated, 1 Huh7, E7386-treated,
- GSM9035237 Huh7, E7386-treated, 2 Huh7, E7386-treated,
- GSM9035238 Huh7, E7386-treated, 3 Huh7, E7386-treated,
- GSM9035239 Huh7, E7386-treated, 4 Huh7, E7386-treated,
- GSM9035240 SNU398, DMSO-treated, 1 SNU398, DMSO-treated,
- GSM9035241 SNU398, DMSO-treated, 2 SNU398, DMSO-treated,
- GSM9035242 SNU398, DMSO-treated, 3 SNU398, DMSO-treated,
- GSM9035243 SNU398, DMSO-treated, 4 SNU398, DMSO-treated,
- GSM9035244 SNU398, E7386-treated, 1 SNU398, E7386-treated,
- GSM9035245 SNU398, E7386-treated, 2 SNU398, E7386-treated,
- GSM9035246 SNU398, E7386-treated, 3 SNU398, E7386-treated,
- GSM9035247 SNU398, E7386-treated, 4 SNU398, E7386-treated,
- GSM9035248 Hep3B, DMSO-treated, 1 Hep3B, DMSO-treated,
- GSM9035249 Hep3B, DMSO-treated, 2 Hep3B, DMSO-treated,
- GSM9035250 Hep3B, DMSO-treated, 3 Hep3B, DMSO-treated,
- GSM9035251 Hep3B, DMSO-treated, 4 Hep3B, DMSO-treated,
- GSM9035252 Hep3B, E7386-treated, 1 Hep3B, E7386-treated,
- GSM9035253 Hep3B, E7386-treated, 2 Hep3B, E7386-treated,
- GSM9035254 Hep3B, E7386-treated, 3 Hep3B, E7386-treated,
- GSM9035255 Hep3B, E7386-treated, 4 Hep3B, E7386-treated,
- GSM9035256 SNU387, DMSO-treated, 1 SNU387, DMSO-treated,
- GSM9035257 SNU387, DMSO-treated, 2 SNU387, DMSO-treated,
- GSM9035258 SNU387, DMSO-treated, 3 SNU387, DMSO-treated,
- GSM9035259 SNU387, DMSO-treated, 4 SNU387, DMSO-treated,
- GSM9035260 SNU387, E7386-treated, 1 SNU387, E7386-treated,
- GSM9035261 SNU387, E7386-treated, 2 SNU387, E7386-treated,
- GSM9035262 SNU387, E7386-treated, 3 SNU387, E7386-treated,
- GSM9035263 SNU387, E7386-treated, 4 SNU387, E7386-treated,
- GSM9035264 MYC-lucOS;CTNNB1 overexpression, C57BL6/J, Vehicle, 1 MYC-lucOS;CTNNB1 overex…
- GSM9035265 MYC-lucOS;CTNNB1 overexpression, C57BL6/J, Vehicle, 2 MYC-lucOS;CTNNB1 overex…
- GSM9035266 MYC-lucOS;CTNNB1 overexpression, C57BL6/J, Vehicle, 3 MYC-lucOS;CTNNB1 overex…
- GSM9035267 MYC-lucOS;CTNNB1 overexpression, C57BL6/J, Lenvatinib, 1 MYC-lucOS;CTNNB1 overex…
- GSM9035268 MYC-lucOS;CTNNB1 overexpression, C57BL6/J, Lenvatinib, 2 MYC-lucOS;CTNNB1 overex…
- GSM9035269 MYC-lucOS;CTNNB1 overexpression, C57BL6/J, Lenvatinib, 3 MYC-lucOS;CTNNB1 overex…
- GSM9035270 MYC-lucOS;CTNNB1 overexpression, C57BL6/J, E7386, 1
- GSM9035271 MYC-lucOS;CTNNB1 overexpression, C57BL6/J, E7386+Lenvatinib, 1 MYC-lucOS;CTNNB1 overex…
+ 4 more — browse all 44 samples with per-sample file links →
- GSE105130 Comprehensive analysis of Transcriptome Profiles in Hepatocellular Carcinoma patients 52 samples same disease briefing · shares hepatocellular
- GSE140228 Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma 41 samples same disease briefing · shares hepatocellular
- GSE14520 Gene expression data of human hepatocellular carcinoma (HCC) 488 samples same disease briefing · shares hepatocellular
- GSE10143 Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma 387 samples same disease briefing · shares hepatocellular
- GSE107170 Molecular Signature of Hepatitis D Virus-Associated Hepatocellular Carcinoma 307 samples same disease briefing · shares hepatocellular
- GSE104580 Using a novel gene signature for predicting the efficacy of the transarterial chemoembolization in patients with hepatocellular carcinoma. 147 samples same disease briefing · shares hepatocellular
- GSE109211 Molecular predictors of prevention of recurrence in hepatocellular carcinoma with sorafenib as adjuvant treatment in the phase 3 STORM trial 140 samples same disease briefing · shares hepatocellular
- GSE10186 Integrative Transcriptome Analysis Reveals Common Molecular Subtypes of Human Hepatocellular Carcinoma 118 samples same disease briefing · shares hepatocellular
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.